Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and normal renal function. Dextrose is a source of calories and fluid. Sodium chloride is an electrolyte replenisher.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment or prevention of hypokalemia,Replacement of potassium in patients with potassium deficiency,Intravenous fluid and electrolyte maintenance
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous, 10-20 m Eq/hour, not to exceed 40 m Eq per dose or 200 m Eq per day; rate not to exceed 1 m Eq/kg/hour. Typical maintenance: 40-80 m Eq/day.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as potassium is not eliminated by first-order kinetics; clearance depends on renal function (GFR) and tubular handling. In patients with normal renal function, plasma potassium declines rapidly after IV infusion, with a distribution half-life of approximately 1 hour and an elimination half-life of 12-24 hours for excess potassium, but this is clinically not used. The terminal half-life is not defined due to physiological regulation.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and subsequent oxidative pathways. Sodium and chloride are handled by renal regulation.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (90% or more) as potassium ion via glomerular filtration and tubular secretion; minimal biliary/fecal (<5%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Negligible; potassium is not significantly bound to plasma proteins (0-10%).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 0.5-0.7 L/kg (total body water); distributes rapidly into extracellular and intracellular compartments, with intracellular concentration (~150 m Eq/L) much higher than extracellular (3.5-5 m Eq/L).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: ~90% as potassium chloride in solution (well absorbed from GI tract). Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR <30 m L/min: avoid use or reduce dose by 50%; monitor potassium levels closely. GFR 30-50 m L/min: reduce dose by 25-50% and monitor. GFR >50 m L/min: no adjustment necessary.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required based on Child-Pugh score; monitor potassium levels due to potential renal complications in hepatic disease.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous, 0.5-1 m Eq/kg/dose, maximum 1 m Eq/kg/hour, not to exceed 30 m Eq per dose; maintenance: 2-3 m Eq/kg/day.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of dosing range (e.g., 10-20 m Eq/day); monitor renal function and serum potassium frequently due to age-related decline in GFR and increased sensitivity.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Do not administer undiluted. Rapid intravenous administration may cause fatal hyperkalemia. Concentrated potassium solutions should be infused via a central line only.
None.
Use with caution in patients with renal impairment, heart disease, or conditions predisposing to hyperkalemia,Monitor serum potassium, glucose, and electrolytes regularly,Risk of hyperkalemia, especially with rapid infusion,Risk of fluid overload in patients with heart failure or renal impairment,Extravasation risk with concentrated solutions
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Severe renal impairment with oliguria or anuria,Addison's disease,Acute dehydration,Heat cramps,Concurrent use with potassium-sparing diuretics or ACE inhibitors (relative)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, tomatoes, salt substitutes) and high-sodium foods if concurrent hyperkalemia or hypertension is a concern. Dextrose content requires carbohydrate counting in diabetic patients; adjust insulin accordingly. No specific food interactions beyond electrolyte content.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride at standard replacement doses are not teratogenic. There are no known fetal risks associated with appropriate electrolyte and fluid administration. High doses leading to maternal hyperkalemia may cause fetal arrhythmias. Dextrose infusion may cause fetal hyperglycemia and hyperinsulinemia, especially if maternal glucose is poorly controlled. No teratogenic effects are reported from any component.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, chloride, dextrose, and sodium are normal constituents of breast milk. Intravenous administration is unlikely to significantly alter milk composition. No M/P ratio is available; however, these components are naturally present and considered compatible with breastfeeding. Maternal electrolyte balance should be monitored, but no adverse effects on nursing infants are expected.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy does not require dose adjustments for potassium chloride, dextrose, or sodium chloride at standard replacement doses. However, increased plasma volume and glomerular filtration rate may alter electrolyte and fluid requirements. Potassium requirements may be similar; glucose tolerance may decrease, so dextrose infusion should be adjusted to avoid hyperglycemia, especially in gestational diabetes. Close monitoring of electrolytes, glucose, and fluid balance is recommended.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Potassium chloride in dextrose 5% and sodium chloride 0.9% provides simultaneous potassium repletion, caloric supplementation, and isotonic volume expansion. Avoid administration at rates exceeding 10-20 m Eq/hour via peripheral line to prevent phlebitis; central line preferred for higher rates. Monitor serum potassium, glucose, and sodium levels frequently, especially in renal impairment, diabetes, or heart failure. High dextrose load may cause hyperglycemia; insulin adjustments may be needed in diabetics. NOT compatible with amphotericin B, diazepam, or phenytoin.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to restore potassium levels, provide sugar, and maintain fluid balance.,Inform your doctor if you have kidney disease, diabetes, heart failure, or are on ACE inhibitors, ARBs, or potassium-sparing diuretics.,Report any pain, redness, or swelling at the injection site, muscle weakness, irregular heartbeat, or numbness/tingling.,Do not adjust the infusion rate yourself; it is controlled by healthcare staff.,You may experience increased urination, thirst, or flushing.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and normal renal function. Dextrose is a source of calories and fluid. Sodium chloride is an electrolyte replenisher.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous, 10-20 m Eq/hour, not to exceed 40 m Eq per dose or 200 m Eq per day; rate not to exceed 1 m Eq/kg/hour. Typical maintenance: 40-80 m Eq/day.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride at standard replacement doses are not teratogenic. There are no known fetal risks associated with appropriate electrolyte and flui. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.